09:15 AM EDT, 08/05/2025 (MT Newswires) -- MoonLake Immunotherapeutics ( MLTX ) reported a Q2 loss Tuesday of $0.87 per share, widening from a loss of $0.39 a year earlier.

Analysts polled by FactSet expected a loss of $0.71.

As expected, no revenue for the quarter ended June 30 was reported.

As of June 30, MoonLake said it had $425.1 million in cash, cash equivalents and short-term marketable securities.

Shares of the company were 0.6% lower in recent premarket activity.